159 related articles for article (PubMed ID: 23624821)
1. Interleukin-15 administration increases graft-versus-tumor activity in recipients of haploidentical hematopoietic SCT.
Sauter CT; Bailey CP; Panis MM; Biswas CS; Budak-Alpdogan T; Durham A; Flomenberg N; Alpdogan O
Bone Marrow Transplant; 2013 Sep; 48(9):1237-42. PubMed ID: 23624821
[TBL] [Abstract][Full Text] [Related]
2. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
3. Haploidentical hematopoietic SCT increases graft-versus-tumor effect against renal cell carcinoma.
Budak-Alpdogan T; Sauter CT; Bailey CP; Biswas CS; Panis MM; Civriz S; Flomenberg N; Alpdogan O
Bone Marrow Transplant; 2013 Aug; 48(8):1084-90. PubMed ID: 23435516
[TBL] [Abstract][Full Text] [Related]
4. Double haploidentical hematopoietic stem cell transplantation results in successful engraftment of bone marrow from both donors without graft-versus-host or graft-versus-graft effects.
Biswas CS; Sauter CT; Bailey CP; Rittenberg D; Luo X; Panis MM; Budak-Alpdogan T; Grosso D; Flomenberg N; Alpdogan O
Biol Blood Marrow Transplant; 2012 Dec; 18(12):1808-18. PubMed ID: 23084958
[TBL] [Abstract][Full Text] [Related]
5. The influence of pretransplantation conditioning on graft-vs.-leukemia effect in mice.
Lim JY; Choi MS; Youn H; Choi EY; Min CK
Exp Hematol; 2011 Oct; 39(10):1018-29. PubMed ID: 21767512
[TBL] [Abstract][Full Text] [Related]
6. [Experimental study on IL-2- and IL-15 application in allogeneic hematopoietic stem cell transplantation].
Chen GH; Wu DP; Sun AN; Yang MZ; Wang Y; Tang XW; Chang HR; Feng YF; Zhu ZL
Zhonghua Xue Ye Xue Za Zhi; 2008 Aug; 29(8):526-30. PubMed ID: 19112915
[TBL] [Abstract][Full Text] [Related]
7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation.
Alpdogan O; Eng JM; Muriglan SJ; Willis LM; Hubbard VM; Tjoe KH; Terwey TH; Kochman A; van den Brink MR
Blood; 2005 Jan; 105(2):865-73. PubMed ID: 15280205
[TBL] [Abstract][Full Text] [Related]
9. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
Drobyski WR; Majewski D; Hanson G
Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
[TBL] [Abstract][Full Text] [Related]
10. New interleukin-15 superagonist (IL-15SA) significantly enhances graft-versus-tumor activity.
Bailey CP; Budak-Alpdogan T; Sauter CT; Panis MM; Buyukgoz C; Jeng EK; Wong HC; Flomenberg N; Alpdogan O
Oncotarget; 2017 Jul; 8(27):44366-44378. PubMed ID: 28574833
[TBL] [Abstract][Full Text] [Related]
11. Flow cytometric analysis of the graft-versus-Leukemia-effect after hematopoietic stem cell transplantation in mice.
Schmidt F; Hilger N; Oelkrug C; Svanidze E; Ruschpler P; Eichler W; Boldt A; Emmrich F; Fricke S
Cytometry A; 2015 Apr; 87(4):334-45. PubMed ID: 25717029
[TBL] [Abstract][Full Text] [Related]
12. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response.
Jones SC; Murphy GF; Korngold R
Biol Blood Marrow Transplant; 2003 Apr; 9(4):243-56. PubMed ID: 12720217
[TBL] [Abstract][Full Text] [Related]
13. Induction of transplantation tolerance in haploidenical transplantation under reduced intensity conditioning: the role of ex-vivo generated donor CD8+ T cells with central memory phenotype.
Ophir E; Eidelstein Y; Bachar-Lustig E; Hagin D; Or-Geva N; Lask A; Reisner Y
Best Pract Res Clin Haematol; 2011 Sep; 24(3):393-401. PubMed ID: 21925092
[TBL] [Abstract][Full Text] [Related]
14. The effect of human IL-2-activated natural killer and T cells on graft-versus-host disease and graft-versus-leukemia in SCID mice bearing human leukemic cells.
Xun CQ; Thompson JS; Jennings CD; Brown SA
Transplantation; 1995 Oct; 60(8):821-7. PubMed ID: 7482742
[TBL] [Abstract][Full Text] [Related]
15. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
16. Separation of antileukemic effects from graft-versus-host disease in MHC-haploidentical murine bone marrow transplantation: participation of host immune cells.
Satake A; Inoue T; Kubo S; Taniguchi Y; Imado T; Fujioka T; Horiuchi M; Xu Y; Ikegame K; Yoshihara S; Kaida K; Tamaki H; Okada M; Okamura H; Ogawa H
Int J Hematol; 2010 Apr; 91(3):485-97. PubMed ID: 20300982
[TBL] [Abstract][Full Text] [Related]
17. Long-term human CD34+ stem cell-engrafted nonobese diabetic/SCID/IL-2R gamma(null) mice show impaired CD8+ T cell maintenance and a functional arrest of immature NK cells.
André MC; Erbacher A; Gille C; Schmauke V; Goecke B; Hohberger A; Mang P; Wilhelm A; Mueller I; Herr W; Lang P; Handgretinger R; Hartwig UF
J Immunol; 2010 Sep; 185(5):2710-20. PubMed ID: 20668220
[TBL] [Abstract][Full Text] [Related]
18. IL-22 deficiency in donor T cells attenuates murine acute graft-versus-host disease mortality while sparing the graft-versus-leukemia effect.
Couturier M; Lamarthée B; Arbez J; Renauld JC; Bossard C; Malard F; Bonnefoy F; Mohty M; Perruche S; Tiberghien P; Saas P; Gaugler B
Leukemia; 2013 Jul; 27(7):1527-37. PubMed ID: 23399894
[TBL] [Abstract][Full Text] [Related]
19. Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease.
Chang YJ; Zhao XY; Huang XJ
Front Immunol; 2018; 9():3041. PubMed ID: 30619371
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
